Quarterly report [Sections 13 or 15(d)]

Significant Strategic Collaborations (Details Narrative)

v3.25.3
Significant Strategic Collaborations (Details Narrative) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Nov. 01, 2025
May 01, 2025
Dec. 31, 2024
Nov. 01, 2024
Mar. 17, 2023
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue $ 1,026,957 $ 614,243 $ 2,210,115 $ 1,851,464          
Research and development expenses 756,482 367,985 2,292,068 2,246,077          
Prepaid expenses and other current assets 946,361   946,361       $ 421,954    
Accounts payable 578,250   578,250       283,615    
Prepaid expenses and other 533,525   533,525       610,648    
Recognized revenue 1,026,957 614,243 2,210,115 1,851,464          
Collaborative Agreements [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Recognized revenue 0 0 0 0          
Takeda [Member] | Royalty Revenue [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Revenue 1,000,000 $ 600,000 2,200,000 $ 1,900,000          
Catalent Pharma Solutions [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development expenses     2,800,000            
Prepaid expenses and other current assets 300,000   300,000       28,000    
Liability and included in accounts payable and accrued expenses and other current liabilities 140,000   140,000            
Accounts payable 70,000   70,000            
Accrued expenses and other current liabilities 70,000   70,000       100,000    
Other assets             300,000    
Scripps Research [Member] | D Nase Technology [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Contractual obligation                 $ 900,000
Contractual obligation addition         $ 300,000 $ 400,000   $ 400,000  
Scripps Research [Member] | Scripps Agreement [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development expenses     1,700,000            
Accrued expenses 100,000   100,000            
Prepaid expenses 0   0       400,000    
Prepaid expenses and other 100,000   100,000            
University Of Virginia [Member]                  
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]                  
Research and development expenses     500,000            
Prepaid expenses and other current assets 100,000   100,000       100,000    
Advance payment $ 30,000   $ 30,000       $ 30,000